Novel safety biomarkers for drug development
Testing the safety of drugs is the most important aspect in the drug development pipeline. Although various safety biomarkers have been proposed, substantial sample sizes are required for their validation. The EU-funded TransBioLine project will capitalise on existing data, resources and international collaborations to establish robust biomarkers for use in drug development. Researchers will also develop and validate assays for new safety biomarkers and implement circulating miRNAs as tissue- and mechanism-specific diagnostic tools. Ultimately, the aim is to obtain approval of safety biomarkers as qualified drug development tools by key regulatory authorities such as the EMA and FDA.
Call for proposal
See other projects for this call
Funding SchemeIMI2-RIA - Research and Innovation action
85718 Tucson Az